BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Laminopathies; Mutations on single gene and various human genetic diseases

  • Kang, So-mi (Department of Molecular Biology, College of Natural Science, Pusan National University) ;
  • Yoon, Min-Ho (Department of Molecular Biology, College of Natural Science, Pusan National University) ;
  • Park, Bum-Joon (Department of Molecular Biology, College of Natural Science, Pusan National University)
  • Received : 2018.04.25
  • Published : 2018.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Lamin A and its alternative splicing product Lamin C are the key intermediate filaments (IFs) of the inner nuclear membrane intermediate filament. Lamin A/C forms the inner nuclear mesh with Lamin B and works as a frame with a nuclear shape. In addition to supporting the function of nucleus, nuclear lamins perform important roles such as holding the nuclear pore complex and chromatin. However, mutations on the Lamin A or Lamin B related proteins induce various types of human genetic disorders and diseases including premature aging syndromes, muscular dystrophy, lipodystrophy and neuropathy. In this review, we briefly overview the relevance of genetic mutations of Lamin A, human disorders and laminopathies. We also discuss a mouse model for genetic diseases. Finally, we describe the current treatment for laminopathies.

Keywords

References

  1. McKenna T, Baek JH and Eriksson M (2013) Laminopathies. Genetic Disorders chapter 2, 28-64
  2. Cronshaw JM, Kruchinsky AN, Zhang W, Chait BT and Matunis MJ (2002) Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 158, 915-927 https://doi.org/10.1083/jcb.200206106
  3. Aebi U, Cohn J, Buhle L and Gerace L (1986) The nuclear lamina is a meshwork of intermediate-type filaments. Nature 323, 560-564 https://doi.org/10.1038/323560a0
  4. Gruenbaum Y and Foisner R (2015) Lamins: Nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. Annu Rev Biochem 84, 131-164 https://doi.org/10.1146/annurev-biochem-060614-034115
  5. Clements L, Manilal S, Love DR and Morris GE (2000) Direct interaction between emerin and lamin A. Biochem Biophys Res Commun 267, 709-714 https://doi.org/10.1006/bbrc.1999.2023
  6. Zastrow MS, Vlcek S and Wilson KL (2004) Proteins that bind A-type lamins: integrating isolated clues. J Cell Sci 117, 979-987 https://doi.org/10.1242/jcs.01102
  7. Salpingidou G, Smertenko A, Hausmanowa-Petrucewicz I, Hussey PJ and Hutchison CJ (2007) A novel role for the nuclear membrane protein emerin in association of the centrosome to the outer nuclear membrane. J Cell Biol 178, 897-904 https://doi.org/10.1083/jcb.200702026
  8. Chang W, Folker ES, Worman HJ and Gundersen GG (2013) Emerin organizes actin flow for nuclear movement and centrosome orientation in migrating fibroblasts. Mol Biol Cell 24, 3869-3880 https://doi.org/10.1091/mbc.e13-06-0307
  9. Constantinescu D, Gray HL, Sammak PJ, Schatten GP and Csoka AB (2006) Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. Stem Cells 24, 177-185 https://doi.org/10.1634/stemcells.2004-0159
  10. Rober RA, Weber K and Osborn M (1989) Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 105, 365-378
  11. Briand N and Collas P (2018) Laminopathy-causing lamin A mutations reconfigure lamina-associated domains and local spatial chromatin conformation. Nucleus 9, 216-226 https://doi.org/10.1080/19491034.2018.1449498
  12. Chojnowski A, Ong PF and Dreesen O (2015) Nuclear lamina remodeling and its implications for human disease. Cell Tissue Res 360, 621-631 https://doi.org/10.1007/s00441-014-2069-4
  13. Worman HJ (2012) Nuclear lamins and laminopathies. J Pathol 226, 316-325 https://doi.org/10.1002/path.2999
  14. Ben Yaou R, Muchir A, Arimura T et al (2005) Genetics of laminopathies. Novartis Found Symp 264, 81-90
  15. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253, 49-53 https://doi.org/10.1126/science.1905840
  16. Fisher D, Chaudhary N (1986) cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Ntl Acad Sci U S A 83, 6450-6454 https://doi.org/10.1073/pnas.83.17.6450
  17. Lin F, Worman HJ (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 268, 16321-16326
  18. Barrowman J, Hamblet C, Geoge CM and Michaelis S (2008) Analysis of prelamin A biogenesis reveals the nucleus to be a CaaX processing compartment. Mol Biol Cell 19, 5398-5408 https://doi.org/10.1091/mbc.e08-07-0704
  19. Barrowman J, Hamblet C, Kane MS and Michaelis S (2012) Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. PLoS One 7, e32120 https://doi.org/10.1371/journal.pone.0032120
  20. Landires I, Pascale JM and Motta J (2007) The position of the mutation within the LMNA gene determines the type and extent of tissue involvement in laminopathies. Clin Genet 71, 592-593 https://doi.org/10.1111/j.1399-0004.2007.00772.x
  21. Broers JLV, Ramaekers FCS, Bonne G, Yaou RB and Hutchison CJ (2006) Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 86, 967-1008 https://doi.org/10.1152/physrev.00047.2005
  22. Coffinier C, Jung HJ, Li Z et al (2010) Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem 285, 20818-20826 https://doi.org/10.1074/jbc.M110.128835
  23. Kitten GT and Nigg EA (1991) The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol 113, 13-23 https://doi.org/10.1083/jcb.113.1.13
  24. Emery AE and Dreifuss FE (1966) Unusual type of benign x-linked muscular dystrophy. J Neurol Neurosurg Psychiatry 29, 338-342 https://doi.org/10.1136/jnnp.29.4.338
  25. Muchir A and Worman HJ (2007) Emery-Dreifuss muscular dystrophy. Curr Neurol Neurosci Rep 7, 78-83 https://doi.org/10.1007/s11910-007-0025-3
  26. Bonne G, Mercuri E, Muchir A et al (2000) Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 48, 170-180 https://doi.org/10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J
  27. Helbling-Leclerc A, Bonne G and Schwartz K (2002) Emery-Dreifuss muscular dystrophy. Eur J Hum Genet 10, 157-161 https://doi.org/10.1038/sj.ejhg.5200744
  28. Stewart CL, Kozlov S, Fong LG and Young SG (2007) Mouse models of the laminopathies. Exp Cell Res 313, 2144-2156 https://doi.org/10.1016/j.yexcr.2007.03.026
  29. Canki-Klain N, Recan D, Milicic D et al (2000) Clinical variability and molecular diagnosis in a four-generation family with X-linked Emery-Dreifuss muscular dystrophy. Croat Med J 41, 389-395
  30. Fatkin D, MacRae C, Sasaki T et al (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341, 1715-1724 https://doi.org/10.1056/NEJM199912023412302
  31. Muchir A, Bonne G, van der Kooi AJ et al (2000) Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances. Hum Mol Genet 9, 1453-1459 https://doi.org/10.1093/hmg/9.9.1453
  32. Yuan WL, Huang CY, Wang JF et al (2009) R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. Chin Med J 122, 2840-2845
  33. McPherson E, Turner L, Zador I, Reynolds K, Macgregor D and Giampietro PF (2009) Ovarian failure and dilated cardiomyopathy due to a novel lamin mutation. Am J Med Genet 149A, 567-572 https://doi.org/10.1002/ajmg.a.32627
  34. Garg A, Subramanyam L, Agarwal AK et al (2009) Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab 94, 4971-1983 https://doi.org/10.1210/jc.2009-0472
  35. Shackleton S, Lloyd DJ, Jackson SN et al (2000) LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24, 153-156 https://doi.org/10.1038/72807
  36. Padiath QS, Saigoh K, Schiffmann R et al (2006) Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 38, 1114-1123 https://doi.org/10.1038/ng1872
  37. Schuster J, Sundblom J, Thuresson AC et al (2011) Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. Neurogenetics 12, 65-72 https://doi.org/10.1007/s10048-010-0269-y
  38. Eriksson M, Brown WT, Gordon LB et al (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298 https://doi.org/10.1038/nature01629
  39. Rodriguez JI, Perez-Alonso P, Funes R and Perez-Rodriguez J (1999) Lethal neonatal Hutchinson-Gilford progeria syndrome. Am J Med Genet 82, 242-248 https://doi.org/10.1002/(SICI)1096-8628(19990129)82:3<242::AID-AJMG9>3.0.CO;2-E
  40. Gillar PJ, Kaye CI and McCourt JW (1991) Progressive early dermatologic changes in Hutchinson-Gilford progeria syndrome. Pediatr Dermatol 8, 199-206 https://doi.org/10.1111/j.1525-1470.1991.tb00859.x
  41. Merideth MA, Gordon LB, Clauss S et al (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358, 592-604 https://doi.org/10.1056/NEJMoa0706898
  42. Salamat M, Dhar PK, Neagu DL and Lyon JB (2010) Aortic calcification in a patient with Hutchinson-Gilford progeria syndrome. Pediatr Cardiol 31, 925-926 https://doi.org/10.1007/s00246-010-9711-z
  43. Gordon LB, Kleinman ME, Massaro J et al (2016) Clinical trial of the protein farnesylation inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in children with Hutchinson-Gilford progeria syndrome. Circulation 134, 114-125 https://doi.org/10.1161/CIRCULATIONAHA.116.022188
  44. Dechat T, Shimi T, Adam SA et al (2007) Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A 104, 4955-4960 https://doi.org/10.1073/pnas.0700854104
  45. Lee SJ, Jung YS, Yoon MH et al (2016) Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype. J Clin Invest 126, 3879-3893 https://doi.org/10.1172/JCI84164
  46. Smigiel R, Jakubial A, Esteves-Vieira V et al (2010) Novel frameshifting mutations of the ZMPSTE24 gene in two siblings affected with restrictive dermopathy and review of the mutations described in the literature. Am J Med Genet 152A, 447-452 https://doi.org/10.1002/ajmg.a.33221
  47. Mok Q, Curley R, Tolmie J and Marsden R (1990) Restrictive dermopathy: a report of three cases. J Met Genet 27, 315-319 https://doi.org/10.1136/jmg.27.5.315
  48. Yu CE, Oshima J, Fu YH et al (1996) Positional cloning of the Werner’s syndrome gene. Science 272, 258-262 https://doi.org/10.1126/science.272.5259.258
  49. Hisama FM, Lessel D, Leistritz D et al (2011) Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. Am J Med Genet 155A, 3002-3006
  50. Hisama FM, Kubisch C, Martin GM and Oshima J (2012) Clinical utility gene card for: Werner syndrome. Eur J Hum Genet 20, 1-3
  51. Goto M, Horiuchi Y, Tanimoto K, Ishii T and Nakashima H (1978) Werner’s syndrome: analysis of 15 cases with a review of the Japanese literature. J Am Geriatr Soc 26, 341-347 https://doi.org/10.1111/j.1532-5415.1978.tb03681.x
  52. Chen L, Lee L, Kudlow BA et al (2003) LMNA mutations in atypical Werner’s syndrome. Lancet 362, 440-445 https://doi.org/10.1016/S0140-6736(03)14069-X
  53. Sullivan T, Escalante-Alcalde D, Bhatt H et al (1999) Loss of A-type lamin expression compromise nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 147, 913-920 https://doi.org/10.1083/jcb.147.5.913
  54. Pendas AM, Zhou Z, Candinanos J et al (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 31, 94-99 https://doi.org/10.1038/ng871
  55. Kubben N, Voncken JW, Konings G et al (2011) Post-natal myogenic and adipogenic developmental: defects and metabolic impairment upon loss of A-type lamins. Nucleus 2, 195-207 https://doi.org/10.4161/nucl.2.3.15731
  56. Fong LG, Ng JK, Lammerding J et al (2006) Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 116, 743-752 https://doi.org/10.1172/JCI27125
  57. Melcon G, Kozlov S, Cutler DA et al (2006) Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and Myo D pathways during muscle regeneration. Hum Mol Genet 15, 637-651 https://doi.org/10.1093/hmg/ddi479
  58. Ozawa R, Hayashi YK, Ogawa M et al (2006) Emerin-lacking mice show minimal motor and cardiac dysfunctions with nuclear-associated vacuoles. Am J Pathol 168, 907-917 https://doi.org/10.2353/ajpath.2006.050564
  59. Pilat U, Dechat T, Bertrand AT et al (2013) The muscle dystrophy-causing ${\Delta}K32$ lamin A/C mutant does not impair the functions of the nucleoplasmic lamin $A/C-LAP2{\alpha}$ complex in mice. J Cell Sci 126, 1753-1762 https://doi.org/10.1242/jcs.115246
  60. Odgren PR, Pratt CH, Mackay CA et al (2010) Disheveled hair and ear (Dhe), a spontaneous mouse Lmna mutation modeling human laminopathies. PLoS One 5, e9959 https://doi.org/10.1371/journal.pone.0009959
  61. Mounkes LC, Kozlov SV, Rottman JN and Stewart CL (2005) Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 14, 2167-2180 https://doi.org/10.1093/hmg/ddi221
  62. Arimura T, Helbling-Leclerc A, Massart C et al (2005) Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 14, 155-169 https://doi.org/10.1093/hmg/ddi017
  63. Wang Y, Herron AJ and Worman HJ (2006) Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet 15, 2479-2489 https://doi.org/10.1093/hmg/ddl170
  64. Wojtanik KM, Edgemon K, Viswanadha S et al (2009) The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation. J Lipid Res 50, 1068-1079 https://doi.org/10.1194/jlr.M800491-JLR200
  65. Mounkes LC, Kozlov S, Hernandez L, Sullivan T and Stewart CL (2003) A progeroid syndrome in mice is caused by defects in A-type lamins. Nature 423, 298-301 https://doi.org/10.1038/nature01631
  66. Varga R, Eriksson M, Erdos MR et al (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 103, 3250-3255 https://doi.org/10.1073/pnas.0600012103
  67. Osorio FG, Navarro CL, Cadinanos J et al (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3, 106ra107
  68. Vergnes L, Peterfy M, Bergo MO, Young SG and Reue K (2004) Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci U S A 101, 10428-10433 https://doi.org/10.1073/pnas.0401424101
  69. Heng MY, Lin ST, Verret L et al (2013) Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model. J Clin Invest 123, 2719-2729 https://doi.org/10.1172/JCI66737
  70. Ambrosi P, Mouly-Bandini A, Attarian S and Habib G (2009) Heart transplantation in 7 patients form a single family with limb-girdle muscular dystrophy caused by lamin A/C mutation. Int J Cardiol 137, e75-76 https://doi.org/10.1016/j.ijcard.2009.04.036
  71. Dyck JD, David TE, Burke B, Webb GD, Henderson MA and Fowler RS (1987) Management of coronary artery disease in Hutchinson-Gilford syndrome. J Pediatr 111, 407-410 https://doi.org/10.1016/S0022-3476(87)80466-3
  72. Ramos FJ, Chen SC, Garelick MG et al (2012) Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescue cardiac and skeletal muscle function, and extends survival. Sci Transl Med 4, 144ra103 https://doi.org/10.1126/scitranslmed.3003802
  73. Choi JC, Muchir A, Wu W and Iwata S (2012) Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C mutation. Sci Transl Med 4, 144ra102 https://doi.org/10.1126/scitranslmed.3003875
  74. Kieran MW, Gordon L and Kleinman M (2007) New approaches to progeria. Pediatrics 120, 834-841 https://doi.org/10.1542/peds.2007-1356
  75. Capell B, Erdos M, Medigan J and Fiordalisi J (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Pro Natl Acad Sci U S A 102, 12879-12884 https://doi.org/10.1073/pnas.0506001102
  76. Fong L, Frost D, Meta M, Qiao X and Yang S (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311, 1621-1623 https://doi.org/10.1126/science.1124875
  77. Gordon LB, Kleinman ME, Miller DT et al (2012) Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 109, 16666-16671 https://doi.org/10.1073/pnas.1202529109
  78. Verstraeten VL, Peckham LA, Olive M et al (2011) Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc Natl Acad Sci U S A 108, 4997-5002 https://doi.org/10.1073/pnas.1019532108
  79. Scaffidi P (2006) Lamin A-dependent nuclear defects in human aging. Science 312, 1059-1063 https://doi.org/10.1126/science.1127168
  80. Osorio FG, Navarro CL, Cadinanos J et al (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3, 106ra107

Cited by

  1. The Cutting Edge: The Role of mTOR Signaling in Laminopathies vol.20, pp.4, 2019, https://doi.org/10.3390/ijms20040847